After B.Riley FBR and Oppenheimer gave Eiger Biopharmaceuticals (NASDAQ: EIGR) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Eiger Biopharmaceuticals yesterday and set a price target of $53. The company’s shares opened today at $12.35.
According to TipRanks.com, Moussatos is a 1-star analyst with an average return of -0.1% and a 41.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $31.25, implying a 153.0% upside from current levels. In a report issued on August 27, Jefferies also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.92 million. In comparison, last year the company had a GAAP net loss of $11.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex.
